Avalyn Pharma Inc Investor Event Transcript, Nov 18, 2026
Avalyn Pharma Inc. (AVLN)
Avalyn Pharma said its inhaled perfenidone, APO1, completed enrollment in a large global Phase 2b study over the summer, with 52-week data expected in the second half of next year. Its base case is another Phase 3 study before approval. Inhaled nintetanib, APO2, has a 12-week proof-of-concept study with data expected late in 2027. AI summary
Conference Transcript - AVLN 2026-11-18
Roger Song, Analyst — Jefferies
All right. Welcome to a 2026 Jeffries Global Healthcare Conference in London. My name is Roger Song, senior analyst, cover SMICAT biotech in the U.S. It is my pleasure to have a five-side chat with Avalon Pham. And then we have a CEO, Ling, and then the CFO Doug here. Welcome.
Ling, CEO
Thank you so much. Nice to be here.
Roger Song, Analyst — Jefferies
Awesome. Ling, why not you give us some one or two minutes overview of Avalon? Because I think 2027 is very transformative for you and then why you're excited.
Ling, CEO
Yeah, thanks so much, Roger. Hi, everybody. Thanks for coming today. So Avalon Pharma is a company focused on a clinical stage portfolio of assets targeting pulmonary fibrosis. It is one of the rare, very deadly diseases in the lung space that we think is in desperate need of better and new options. What I mean by that, survival with this disease is about three to five years. There are a few drugs approved, but it's only about 10% of patients over the course of a year that are diagnosed with this deadly disease are able to access any of those existing oral medicines, fundamentally because the drugs that exist are almost impossible to tolerate. So they add very difficult GI side effects on top of the already very difficult symptoms of the disease, and for that reason, patients that might try them often will cycle off therapy within a few months. What we're doing at Avalon is taking those same drugs that exist, the two that have been around for about 10 years. They're called perfenidone and nintetanib. We think that rather than delivering them orally, it's much more sensible to deliver them to the lung directly with an inhalation. When we do that, because we're focusing the drug in the lung, we can drop the dose considerably as compared to the oral version. So perfenidone, as an example, goes from 2,400 mg a day to 200, but we actually have better exposure in the lung than the oral. We think that is translating in the clinical data to better efficacy with this approach. And at the same time, when you avoid your systemic exposure by focusing it in the lung and drop the dose, your systemic exposure is much lower than you'd have with the oral. And we think that is now what's resolving and largely addressing the tolerability issues that are the rate limiters to adoption. So our view is it's a sensible approach, high probability of success, given that we're working with drugs that we know work, and delivering them in a better way that makes it accessible for patients. We think fundamentally the approach will really change the product profiles for the better and fundamentally allow us now to access the majority of patients in the marketplace that are just not being treated today. So we have a clinical stage portfolio, as I mentioned. We have a drug, the inhaled profanedone, APO1, that completed enrollment in a large global Phase 2b study over the summer. It's a 52-week study, so we'll have data back from that in the second half of the year next year. We also have a Phase 2 ongoing for our inhaled nintetinib, that's APO2, Another global phase two study. That one's more of a proof of concept, 12-week study. We think we'll have data back from that program late in 2027. And then last week, we announced, actually, that we've advanced our combination product. That's called APO3, and that's a fixed-dose combo of those two monotherapy ingredients. We advanced that into a phase one study, and so that phase one is now starting up, and we think we'll have that one fully reading out again in the second half of next year. So, Roger, to your point, it's going to be a really busy second half of 2027, Evan, but we're just so excited for what we hopefully can do to help these patients.
Roger Song, Analyst — Jefferies
Excellent. Okay, that's a great overview. Lane, we have a lot to cover today, but probably the focus will be APO1 and APO2, but APO3 is definitely a very interesting and a bit earlier stage. So for APO1, the MIS phase 2B, so that is a statistical power for efficacy. And then just tell us what is the goal here? So in terms of you want to improve the efficacy compared to oral version, or how likely are you going to achieve that? And then if you achieve that, would that change your regulatory perspective in terms of the next step in approval?
Ling, CEO
Yeah, great question. Thank you, Roger. So I will say that when I joined the company, I started doing some market research with doctors and patients, and I was actually shocked to understand how much improving tolerability alone matters. So for us, when we think about kind of our base case in a product presentation, we think about just improving tolerability as compared to the existing orals. You know, we think any change in tolerability can really be significant in terms of commercial potential. Doug maybe can speak more to that. We have a recent example of that. So Jascade is launching now. It's a drug from BI. Just a slight improvement in tolerability over the oral nitetinib, and they're really doing great commercially. So tolerability advantage is really meaningful and important in this market. But the clinical data that we have suggests that we can not only improve tolerability, but that we can also improve the efficacy in a very substantial way. If we can do both of those, we think of this as being a bit of a game changer in this field. It should really allow patients now to be treated much better over a much longer-term horizon. We have data in patients that have been in the program for beyond five years, which is remarkable given the survival and the disease. It just speaks to what we might be able to do here to actually change the course of the diagnosis and perhaps extend lives, and that obviously is going to add commercial value as well. So both are important, but just a tolerability advantage will add a lot of value. In terms of regulatory pathway, you know, we're assuming that MIST, which is our APO1 Phase 2B, has been designed as a dose-ranging study, but really designed with Pivotal in mind. And what I mean by that, it's more than 90% power to detect a signal for the high dose versus placebo. It's one year in duration. It's 398 patients. So our view is that from a conservative kind of base case perspective, we expect that we'll likely have another Phase 3 to do after that for approval. There could be an upside to that plan. You know, we'll certainly talk to the agency about MIST and whether or not there might be upsides based on data. But I think the most conservative plan, the one that we're assuming is our base case, is that we'll have another Phase 3 to do after this for approval. Got it.
Roger Song, Analyst — Jefferies
Yeah. So we know the oral ones also works, and then if you achieve parity on the efficacy, and then that's probably the base case, and if you get higher efficacy, you will strive for maybe a little bit different or accelerated regulatory pathway. So what could be the potential you can run another phase three, but in different indication, IPF? You know, sorry, we didn't mention the semester in PPF. So how likely are you going to run a phase three in IPF and then get a label for both? Do we, you know, when you talk with, I think that's a possibility, but have any numbers FDA really looking for? Like, okay, you have a 10, 20% higher than the standard of care, and then we can look at this. Because it's a placebo, and it's a cross-trial comparison.
Ling, CEO
Yeah, it's a good question. I don't think we know strictly what the number is that they're looking for. I think in our minds it's going to be a data issue. We'll see what the data suggests and then see what the right conversation is to have with the agency. As I said, I think that equivalent efficacy to the orals but a change on tolerability is certainly a really viable opportunity, again, because most patients can't stay on these medicines because of the tolerability profile. But we'll have to talk to the agency about that. In terms of your question about IPF and PPF, it might be helpful for the audience just to speak for just a minute about what those two diseases are. So I trust, I'm guessing most people in the room have heard of IPF. It's idiopathic, meaning we don't know the reason for the disease onset. The difference between it and PPF, PPF is not idiopathic. So PPF is driven often by an underlying diagnosis. There's kind of a universe of possible underlying diagnoses. The ones that we see most commonly in the clinic are patients that have systemic autoimmune diseases. They go on to develop interstitial lung disease because of those autoimmune diseases like rheumatoid arthritis. And when the interstitial lung disease sets in, they get an upregulation in inflammation that leads to downstream fibrosis. So that is now called PPF. The FDA has asked us to distinguish clinically between studying IPF and PPF. But the pathophysiology of the two diseases is the same. Fibrosis is fibrosis. So we've learned how to study PPF correctly, and there's some nuances to how we do that, Roger, which we can happily talk about if that's helpful. It involves a set of inclusion criteria that BI developed in their nintetinib program. We call it the in-build criteria. When we use those criteria in PPF, we're essentially picking patients to study who are analogous to IPF in terms of their rate of downward decline in lung function. And when we use those criteria, we've generated now data that's really superimposable across the two populations in IPF and PPF, Both in the nintetinib program and now the neuroendomalase program. So we're using those same criteria in our study. And so to your question, I think to the extent that we're going to do a Phase III after MIST, we would prefer to do it in IPF so that perhaps we can come to market with both indications. But, again, that's going to be a discussion with the agency. So happy to update you on that conversation once we have it.
Roger Song, Analyst — Jefferies
Okay, so you definitely mentioned this trial design and the in-built criteria. I know you have a good team, you know, to design the trial. And then just how much the base, I believe you will release the baseline blinded data early next year as well. So what are the key elements of the baseline characteristics we should pay attention and then that will potentially impact the final outcome? I'm thinking about, you know, prior therapy, nintetanib versus the JASK, and then some of the other, you know, baseline, you know, FEC. So what are the key components we should pay attention, and then how this will impact the outcome?
Ling, CEO
Yeah, it's a great question. So Roger mentioned we have a great team. I should kind of give him a shout-out. Most of our clinical team came from Borenzer-Ringelheim. They developed the oral nintetanib there and then the neuroendomalast as well. So those are the folks that work for us. So I would say to you that as we put this program together, actually all the programs, we were really informed by kind of the experience that that team had and how to develop these drugs correctly, how to do them at the right sites, how to pick the right patients. So, you know, in terms of thinking about baseline characteristics, you're right, we will aim to release that, assuming the abstract is accepted in the first half of the year next year. So you'll see that likely before the data. But I would say that it's probably going to be somewhat comparable to the neuroendomalase PPF data. So their pivotal trial in PPF is called Fibronir, and I would say it's probably going to be similar in that regard. So you're going to want to be looking for the number of patients on background therapies. You're going to want to be looking for what kinds of underlying diagnoses the patient population had. We always look and we're careful to think about the geographic dispersity, too, so we want to make sure that we're studying patients, in this case in the U.S. and Europe and in other places that we're doing the study and to make sure it's kind of well-balanced in that regard.
Roger Song, Analyst — Jefferies
Okay, so when you say well-balanced, if it's not that, as, as. So would that be a material impact outcome, or how should we think about when we see the data? Or you just think the base case is going to be very balanced?
Ling, CEO
Yeah, I think, you know, we just are focused on quality trials and quality execution and operations. So I don't know that it would actually impact the outcome. I just think that's the characteristic of a well-run trial is to see a nice geographic distribution. It was interesting, I mean, just since you're asking, to spend a minute on this. Neuroendomolast's pivotal study was the first time that we've seen an oral drug, neuroendomolast, used on top of background therapy, profenadone and nintetinib. That's what we're working with. You know, everyone else in the space that's doing work with novel mechanisms is studying their novel mechanisms on top of background therapy. So it was interesting to see that neuroendomolast data. What you see, you can look at the background group, so you can look at the group that had no background, the group that had nintetinib background, profenadone background, And you actually see an equal treatment effect of neuroendomalast, irregardless of what the background was. After that, we then got data from the TiVazo program, the treprostanil. It's an inhaled nebulized therapy in the same diseases, same backgrounds. So if you look at that data, treprostanil was actually not effective, not STAT-SAG in either Phase III trial and IPF in patients that were not on background. It was only effective on top of patients that were on profanidonin and tetanib. And the treatment effect was significantly larger for patients that were on background. So just some interesting data. But what it tells us fundamentally is that based on those two trials, it does not appear that allowing background therapy is going to limit your treatment effect. It may only actually improve it. The reason being that patients now coming into these trials, you can see this on background characteristics, based on characteristics, patients coming into these trials that are on background are often older, sicker, more frail, more in need of therapies. So you can see the decline that's more profound in the placebo groups in both studies.
Roger Song, Analyst — Jefferies
Got it. Yeah, that's very helpful. And then this is an inhaled version of profanedone and then intanimate, the APO2. So how should we think about access from the payer side, and then what's been the discussion going on? And then we know that JASK is definitely starting to use it in that case, but also still limited use case yet.
Doug, CFO
Yeah, it's something very timely. We just had a pair at board last week. And at the moment, pulmonary fibrosis is not a top 100 disease for pairs. Of course, that could evolve over time. Jascade is quite an interesting case study. That's the oral neuromodomalase, which was approved around this time last year, launched by Borger-Engelheim. That product was priced at a premium to the historical prices of the oral branded products. It's about $200,000 per annual cost per patient. That product is currently doing an annualized run rate of about over $2 billion in gross sales. And what's happening in the category with a product like that is there's relatively soft step edits. So really a physician is attesting that a patient has either attempted to try one of the two orals and not being able to tolerate it. So I think broadly speaking, we would expect this level of step edits, which is in this category where patients are coming on to these medicines, not able to tolerate. You think about the patient pool kind of in thirds. So one large group of patients that have attempted the orals, can't tolerate them, are waiting for new medicines. Patients that are naive and very reluctant to attempt an oral, just given the perception of the GI issues, which are real. And then patients that are on medicine that can cycle off. So it's really a unique time in pulmonary fibrosis to bring novel medicines to market. And we're seeing that real time with Jascade. And just as a reminder, similar efficacy is the orals, marginally better tolerability with diarrhea being the big liability. But with that said, wide adoption. And that really speaks to our base case of improving, significantly improving tolerability. Where if we show that efficacy is similar is a base case. The upside case, if we're improving efficacy above the orals, we think of that as a kind of a grand slam opportunity for us. So really excited about what's happening in the market.
Ling, CEO
Got it. Can I make one more comment just about the market just while we're on the topic? Because I think it's always helpful to remind people of how big an opportunity this can be. What I mean by that is that, you know, OFEV is considered a very successful product. It certainly is commercially. It's about a $4 billion drug globally in sales. As Doug said, JASCade's off to a great start, $2 billion run rate in its first year. But if you think about just U.S. market for a minute, so U.S. market alone, there are about 300,000 patients diagnosed today with one of the two forms of pulmonary fibrosis, IPF and PPF. If you dollarize the market using the lowest brand pricing today, it's $150,000 per patient per year. That's a U.S. market size today, assuming everyone is only on one drug, of $42 billion. So hopefully through that lens, you've now understood how few patients they're reaching because of the tolerability profile. So again, OFEV, great product, $4 billion commercially, but it's a $42 billion market. So as Doug said, there's just a lot of value to be unlocked here, a lot of patients that we can treat with better tolerability and hopefully for better efficacy as well.
Roger Song, Analyst — Jefferies
Got it. Okay, that's a one drug, already $42 billion market. And then how do you think about this polypharmacy? Because we saw that in many other respiratory diseases and, you know, start with some of the rare diseases as well. So what's the peer feedback, just, you know, as you probably just had a conversation with them. So do they really allow those kind of cold, you know, to dual-branded drug? And how do you think about the overall pricing in this rare disease framework?
Doug, CFO
Yeah, and it's one of the benefits of the trial design of MIST, where we have a cohort of patients that will be on the background, either an intentative, or in some cases, JASCAD, and the neuroendomal asthma are predominantly an intentative. So having that data to show the clinical benefit, I think, is important. And there's analogous examples, whether it's PAH, where multiple loose combinations of brands are being used together. So it's a conversation that payers are open to. Of course, it will come down to prior authorization, step edits, but we feel very confident that similar to other, whether it's asthma, COPD, PAH, this market is going to transition to more combination uses as more medicines are being able to use in combination. Right now, it's not possible with the tolerability challenges.
Roger Song, Analyst — Jefferies
Are they starting to cover some of the dual brands, or it's still kind of early days or very special kind of improvement?
Doug, CFO
It's a good question. You know, Jascade, given the diarrhea liability, if that's used in combination with an intentative, which they did show in the study, that's exacerbated. So two products with diarrhea combined, of course, it's not surprisingly, that's debilitating. So there's limited combination use currently in the pulmonary fibrosis market. But I think we think of ourselves, especially with APO3 on the horizon, as a company that has a very strong strategy to leverage the combination approach going forward.
Ling, CEO
Yeah, and I think fundamentally, exactly as Doug said, that's what we're all about. Fundamentally, we can't, as a field, evolve the treatment algorithm to pulmonary fibrosis yet because the orals are so impossible to tolerate. So you need to first solve that problem. I think the inhaled delivery does it, and that's going to allow us to step up to combos. You know, we're genuinely enthusiastic. There are other companies in our field doing work with other systemic molecules, novel mechanisms. You know, they're all studying them, by the way, on top of standard of care, which is what we're working with. So we're genuinely hopeful for patients' sake that they'll succeed as well and that hopefully we'll be in a situation where we can use loose combos of maybe R-drug with one of those systemics as a loose combo for patients, maybe in the future more fixed-dose combos, but it's fundamentally about, again, making them possible to combine. Today, we just can't combine them in terms of the real world.
Roger Song, Analyst — Jefferies
Yeah. Hopefully, future Evelyn will be the background therapy, and then everyone working on the novel mechanism, and then can use it on top of you, and then you're all with the user.
Ling, CEO
Yeah, exactly. That's what we hope.
Roger Song, Analyst — Jefferies
Okay, good. And then on the APO2, so as you said, Lynn, it is a proof of concept. It is ex-US. How should we think about the US strategy, particularly what's the next step for the APO2?
Ling, CEO
Yeah, sure. Thanks, Roger. So when we talked to the agency about the APO2 program, they asked us to do some additional device compatibility work. Completing that would have slowed our ability to get started with APO2. We were eager to go. And so we decided to do that study, XUS. They also had some questions about nonclinical talks. We thought we were just in the best position to go ahead and do that study, XUS, because no one else had these requests or questions. So we went ahead and started the study up, XUS. In the meantime, we completed that device compatibility work successfully. And so, you know, I think we think that when we have this data package back, again, it's a 12-week proof of concept, that we'll be in a good position to go re-engage the agency and have that conversation about the next steps with that program, you know, aiming for phase three. Important to say that in our field, lots of companies do this same pathway, kind of do phase twos ex-US, and then try to come back into the U.S. for phase three, including oral nintetinib. So it's been a strategy that's been very successfully employed by many folks in our space before.
Roger Song, Analyst — Jefferies
Okay. This is a proof concept. What will be the target profile you want to achieve for the Phase 2a, and then you can move into the, you say you're aiming Phase 3. What will be able to enable the next step will be the Phase 3?
Ling, CEO
Yeah, sure. So the inhaled nintetinib, the APO2 program, Doug mentioned earlier, nintetinib's primary liability is diarrhea. And so when we did the Phase 1 work, you know, we were looking closely for diarrhea. I'm delighted to tell you, and I still get goosebumps when I say it, we didn't see any diarrhea in the Phase 1 program, And that's, we think, owing to the fact that we're dropping that dose. Oral nintetinib is 150 mg. We think the right dose with the inhaled is either 2 or 4. So we have between 17 and 26 times less plasma exposure. And we think that's what's giving us now that ability to improve diarrhea. So this phase two proof of concept is a 12-week study. If you look at the curve with oral nintetinib in terms of discontinuations, you know, it's about 50% of patients are going to discontinue that therapy within a few months. And so our view is that 12 weeks is really enough to really get a good sense now for what amount of diarrhea we're going to see in that program. That is the primary objective of that 12-week proof of concept. On the efficacy side, you know, we always want to do proper dose ranging to satisfy the FDA. And so in this study, we're looking at a 4-mig inhalation and a 2. If you look back historically at the oral nintetinib program, you saw a very clear separation of the doses at between 4 and 6 weeks. By 12 weeks with the oral, it was enough. So our view is that really 12 weeks with the inhaled, given that, by the way, we're 27 times higher in lung exposure than the oral, even at that fraction of a dose, we think 12 weeks is going to be enough to observe a difference between the doses and then pick the right dose to get into phase 3. So that's the objective.
Roger Song, Analyst — Jefferies
Got it. Less diarrhea than the oral, and hopefully at least a separation in the doses so that we can get the right dose into phase three. Got it. Okay. I don't see many competitors in the pipeline in terms of the different formulation or different ways to using the same pathway in terms of the background, the orals. You using the nebulizer, I see one is a DPI, maybe one is an oral, different form of the perfamidone. So how do you think the nebulizer is the right approach to transform this background, perfamidone and nintetinib?
Ling, CEO
Yeah, thank you for the question. So we actually formulated both. So with our nintetinib program, we formulated a dry powder inhaler and a nebulizer. We decided to use the nebulizer for kind of two big reasons. With Profenidone, which is the APO1 program, the volume of drug prohibits any quick inhaler. So the nebulizer is the only game in town. But more importantly for the patients, I want you all to see if you can imagine, and I wish we had video, hopefully we'll get some video, of what these patients are like. So this is not me and you. These are like grandparents who typically have breathlessness. They have a lot of issues with cough. They're quite old, frail. Many of them are on oxygen. And so we really wanted to think carefully about what the right way to actually allow the patients to dose was. So a dry powder inhaler is a single-dose inhaler. I should say, by the way, this patient population, about 70% of the time, has a symptom of cough as part of their disease. A dry powder inhaler requires a vigorous inhalation. There's no propellant. So I don't have one, but it would be like this. So I can do that because I've got good inhalation capacity. I only have mild asthma, but a patient with this disease is going to have a hard time doing that, and if you're relying on one breath to dose and you've got cough, a dry powder inhaler throws a bunch of dry powder on the back of your throat, and guess what? Makes you cough. So our view is that it's a little scary clinically to rely on a DPI because you're likely to cough it right back out, not get enough drug on board. The nebulizer, we're using a handheld nebulizer. It's manufactured by Pari, the same device that InzMed uses for AeroCase. So it's 510K approved. We have a license to it, and importantly, we have exclusivity in it in these molecules. But what's great about it is it doesn't require any kind of special breathing. So it kind of customizes itself to each of your breathing capacity. So it's just normal tidal breathing. You put the mouthpiece in your mouth, and you breathe in and out normally. You're going to be relying on time to dose. So it's about eight and a half minutes twice a day. And you're going to use somewhere between 100 and 200 breaths to dose. So even if you cough once or twice in the beginning, which might happen, you're still going to be able to get enough drug on board to see efficacy. So it's really for patience sake that we want to keep it in that device because we think it's the right way to dose these folks.
Roger Song, Analyst — Jefferies
Awesome. Thank you so much, Ling. Thank you so much, Adag. Thank you, everyone.
Ling, CEO
Thank you.